La Jolla Pharmaceutical (LJPC) announced that it had obtained positive results for its phase 2 study treating patients with a rare disease known as hereditary hemochromatosis ((HH)). These were results from an interim analysis, but based on what was shown, patients treated with LJPC-401 had a good clinical outcome. The future of the biotech lies with several other products in the pipeline. GIAPREZA is another product that has already been approved by the FDA, but sales have been modest for the time being. Especially, the most recent quarter, where sales of the drug